Definition and epidemiology
Type 1 diabetes mellitus is defined by autoimmune-mediated destruction of pancreatic beta cells, resulting in absolute insulin deficiency and lifelong dependence on exogenous insulin.
- Accounts for roughly 5-10% of all diabetes cases
- Peak incidence in childhood and adolescence (two peaks: ages 4-6 and 10-14), but up to half of new cases are diagnosed in adulthood
- Incidence is rising globally, with wide geographic variation (highest in Scandinavia, lowest in East Asia)
- No strong sex predilection
- Strongly associated with other autoimmune diseases (autoimmune thyroiditis, celiac disease, Addison disease, vitiligo, pernicious anemia)
- T1DM causes absolute insulin deficiency; T2DM causes relative deficiency with insulin resistance
- HLA-DR3 and HLA-DR4 are the strongest genetic associations
- Monozygotic twin concordance is only 30-50%, implicating environmental triggers
- Autoantibodies (GAD65, IA-2, ICA, IAA, ZnT8) mark the disease but C-peptide reflects actual insulin reserve
- DKA is far more common in T1DM because residual insulin in T2DM usually suppresses ketogenesis
- Nocturnal enuresis in a previously continent child is a classic early clue
- DCCT trial proved tight glycemic control reduces microvascular complications
- Screen T1DM patients for celiac disease and autoimmune thyroiditis
Etiology and risk factors
T1DM results from a combination of genetic susceptibility and environmental triggers that initiate autoimmune beta-cell injury.
Genetic factors
- Strongest association with HLA-DR3 and HLA-DR4 (HLA class II, chromosome 6)
- Family history increases risk, but most patients have no affected first-degree relative
- Concordance in monozygotic twins is only about 30-50%, indicating a major environmental contribution
Environmental and immune triggers
- Viral infections (coxsackievirus B, enterovirus, congenital rubella) proposed as triggers via molecular mimicry
- Early cow's milk exposure and vitamin D deficiency have been studied as possible contributors, though evidence is inconsistent
- Autoimmune markers: glutamic acid decarboxylase (GAD65) antibodies, islet cell antibodies (ICA), insulin autoantibodies (IAA), and IA-2 antibodies
LADA
- Latent autoimmune diabetes in adults is a slow-onset variant presenting after age 30, often misclassified initially as type 2 diabetes
Pathophysiology
T1DM is a T-cell mediated autoimmune process directed against pancreatic beta cells.
- CD4+ and CD8+ T lymphocytes infiltrate the islets of Langerhans (insulitis), destroying beta cells
- Autoantibodies (anti-GAD65, ICA, IAA, anti-IA-2, anti-ZnT8) are markers of the process, not the primary mediators of damage
- Progressive beta-cell loss eventually causes insulin levels to fall below what is needed to maintain normoglycemia; symptoms typically appear once roughly 80-90% of beta-cell mass is destroyed
- Absolute insulin deficiency means unchecked lipolysis and hepatic ketogenesis, which is why DKA is the classic presenting or complicating event (unlike type 2 diabetes, where residual insulin usually prevents ketosis)
- Loss of insulin's anabolic, anti-lipolytic, and glucose-uptake-promoting effects produces the catabolic state (weight loss, muscle wasting) typical at onset
Clinical features
Onset is often abrupt, over days to weeks, especially in children.
- Polyuria, polydipsia, polyphagia with unintentional weight loss
- Fatigue and blurred vision (osmotic lens changes)
- Nocturnal enuresis in previously toilet-trained children (classic clue)
- Up to 25-40% of children present for the first time in diabetic ketoacidosis: nausea, vomiting, abdominal pain, Kussmaul breathing, fruity (acetone) breath odor, altered mental status
- Signs of dehydration: dry mucous membranes, poor skin turgor, tachycardia, hypotension
- Absence of obesity and acanthosis nigricans helps distinguish from type 2 diabetes, though overlap exists
Diagnosis
Diagnosis combines standard diabetes glycemic criteria with features that point to autoimmune, insulin-deficient disease.
Diagnostic criteria (any one, per ADA/WHO)
| Test | Diagnostic threshold |
|---|---|
| Fasting plasma glucose | ≥126 mg/dL (7.0 mmol/L) |
| 2-hour OGTT glucose | ≥200 mg/dL (11.1 mmol/L) |
| HbA1c | ≥6.5% |
| Random glucose | ≥200 mg/dL with classic symptoms or hyperglycemic crisis |
Supporting work-up to confirm type 1 etiology
- Islet autoantibodies: GAD65, IA-2, insulin, ZnT8 (positive in most new-onset cases)
- C-peptide level: low or undetectable, reflecting minimal endogenous insulin production
- Screen for associated autoimmune disease: TSH, celiac serology (tissue transglutaminase IgA)
- At presentation, check venous blood gas, ketones (serum or urine), and electrolytes to exclude DKA
Differential diagnosis
- Type 2 diabetes mellitus - usually older, obese, insulin resistance, acanthosis nigricans, residual C-peptide, rarely ketosis-prone
- Maturity-onset diabetes of the young (MODY) - autosomal dominant, strong family history, negative autoantibodies, often normal weight
- LADA - adult-onset, slower progression, initially may not need insulin, but autoantibody positive
- Secondary diabetes - due to cystic fibrosis, hemochromatosis, pancreatitis, or glucocorticoid use
- Gestational diabetes - onset during pregnancy, resolves postpartum in most cases
- Diabetes insipidus - polyuria/polydipsia but normal blood glucose, distinguished by water deprivation test
Management
Management is lifelong exogenous insulin replacement plus structured monitoring and education; guidelines from the ADA, ISPAD, and EASD converge on these principles.
Insulin therapy
- Basal-bolus regimens (long-acting basal insulin plus rapid-acting insulin with meals) or continuous subcutaneous insulin infusion (insulin pump) are standard
- Insulin requirements are individualized and adjusted based on carbohydrate intake, activity, and glucose trends
- Continuous glucose monitoring (CGM) is now widely recommended and improves glycemic control and reduces hypoglycemia
Glycemic targets
- HbA1c target is generally <7% in adults, with individualized targets in children and those at risk of severe hypoglycemia (ISPAD/ADA)
Acute management of DKA
- IV fluids, IV insulin infusion, careful potassium repletion and monitoring, and gradual correction to avoid cerebral edema in children
Adjunct and supportive care
- Carbohydrate counting and structured diabetes education
- Regular screening for microvascular complications and associated autoimmune conditions
- Psychosocial support, given high rates of diabetes distress and disordered eating in this population
- Pancreas or islet cell transplantation is reserved for select cases (e.g., with kidney transplant) and not standard first-line care
Complications and prognosis
With modern insulin therapy and monitoring, life expectancy has improved substantially, but complication risk is tied closely to long-term glycemic control.
Acute
- Diabetic ketoacidosis
- Hypoglycemia (a major limiting factor in therapy)
Chronic microvascular
- Diabetic retinopathy (leading cause of adult blindness)
- Diabetic nephropathy (leading cause of end-stage renal disease in many countries)
- Diabetic neuropathy (peripheral and autonomic)
Chronic macrovascular
- Accelerated atherosclerosis increasing risk of coronary artery disease, stroke, and peripheral arterial disease
- Tight glycemic control (demonstrated by the landmark DCCT trial) significantly reduces microvascular complication risk
- Ongoing risk of other autoimmune disease over the patient's lifetime
"DKA WARNS": Dehydration, Ketones, Acidosis, Weight loss, Abdominal pain, Rapid breathing (Kussmaul), Nausea/vomiting, Sugar high (hyperglycemia) — features suggesting new-onset T1DM presenting in DKA.
Practice questions
1. A 9-year-old boy is brought to the emergency department with a 3-day history of vomiting and abdominal pain. His mother reports he has been drinking large amounts of water and has started wetting the bed again after being dry for two years. Vital signs show tachypnea and tachycardia. Fingerstick glucose is 480 mg/dL. Which of the following laboratory findings would be most expected?
2. A 24-year-old woman with new-onset type 1 diabetes is being counseled about long-term risk reduction. Which historical clinical trial established that intensive glycemic control reduces the risk of microvascular complications in type 1 diabetes?
3. A 35-year-old woman initially diagnosed with type 2 diabetes and started on metformin has persistently poor glycemic control despite good adherence. She is lean, has a history of autoimmune thyroiditis, and her C-peptide level returns low. Islet cell antibodies are positive. Which of the following best describes her condition?
Frequently asked questions
What causes type 1 diabetes?
Type 1 diabetes is caused by autoimmune T-cell mediated destruction of insulin-producing beta cells in the pancreas. Genetic susceptibility, especially HLA-DR3 and HLA-DR4, interacts with environmental triggers such as viral infections to initiate this process. The result is progressive, irreversible loss of insulin production, eventually causing symptomatic hyperglycemia once most beta-cell mass is destroyed.
What are the first symptoms of type 1 diabetes?
The first symptoms are usually polyuria, polydipsia, unexplained weight loss, and fatigue, developing over days to weeks. In children, new-onset bedwetting after being toilet trained is a classic early clue. Some patients, particularly children, first present in diabetic ketoacidosis with vomiting, abdominal pain, and rapid breathing, so these symptoms should never be dismissed as a simple viral illness.
How is type 1 diabetes diagnosed?
Diagnosis uses standard glycemic criteria: fasting glucose at least 126 mg/dL, random glucose at least 200 mg/dL with symptoms, HbA1c at least 6.5%, or an abnormal oral glucose tolerance test. Type 1-specific features confirming the diagnosis include positive islet autoantibodies (GAD65, IA-2, ZnT8, IAA) and a low or undetectable C-peptide level, which reflects minimal remaining endogenous insulin production.
Is type 1 diabetes curable?
No, type 1 diabetes is not currently curable and requires lifelong insulin replacement. Beta-cell destruction is permanent once established, though research into islet transplantation, immunotherapy, and artificial pancreas systems continues to improve outcomes. Pancreas or islet transplantation can reduce or eliminate insulin need in select patients, usually those also needing a kidney transplant, but this is not a cure available to most patients.
Type 1 vs type 2 diabetes — what is the difference?
Type 1 diabetes is an autoimmune disease causing absolute insulin deficiency, typically presenting in children or young adults who are often lean, with a tendency toward ketoacidosis. Type 2 diabetes involves insulin resistance with relative insulin deficiency, usually in older or obese adults, with a slower onset and lower risk of spontaneous ketosis. Autoantibody and C-peptide testing can distinguish them when the clinical picture is unclear.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: E10
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.